We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Adam Kibel

Adam Stuart Kibel MD

Professor of Surgery, Harvard University, Cambridge, Massachusetts; Chief of Urology, Brigham and Women’s Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts

Dr. Kibel is a Professor of Surgery at Harvard University, the Chief of Urology at Brigham and Women’s Hospital /Dana Farber Cancer Institute and Chairman of the Harvard Residency Program (Longwood).  He is Co-Director of the DFCI/Harvard Cancer Center Prostate Cancer Program. 

Disclosures

  1. Serve(d) on Ad boards for Dendreon and Sanofi Aventis

Recent Contributions to PracticeUpdate:

  1. Salvage vs Adjuvant Therapy in High-Risk Prostate Cancer
  2. Optimizing Staging in Bladder Cancer
  3. Neoadjuvant Therapy for Locally Advanced Prostate Cancer
  4. Degarelix in Prolonging the Off-Treatment Interval in Men With Localized Prostate Cancer Receiving Intermittent ADT for Biochemical Recurrence Following Radical Local Therapy
  5. A Systematic Review and Framework for the Use of Hormone Therapy With Salvage Radiation Therapy for Recurrent Prostate Cancer
  6. When All Is Said and Done, Screening Decreases Prostate Cancer Mortality: ERSPC and PLCO Trials
  7. Functional Outcome Results From Radical Prostatectomy After Several Prostate Biopsies
  8. A Randomized Comparison Evaluating Changes in Bone Mineral Density in Advanced Prostate Cancer: Luteinizing Hormone–Releasing Hormone Agonists vs Transdermal Estradiol
  9. EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer

Most Read This Week

Recently Updated